H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Context Therapeutics (CNTX – Research Report) today and set a price target of $6.00. The company’s shares closed yesterday at $2.03.
According to TipRanks, Bodnar is a 3-star analyst with an average return of 3.6% and a 55.56% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as NovoCure, Celsion, and Nkarta.
Currently, the analyst consensus on Context Therapeutics is a Moderate Buy with an average price target of $6.00.
See the top stocks recommended by analysts >>
Based on Context Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $3.44 million. In comparison, last year the company had a GAAP net loss of $892.05 thousand
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer.
Read More on CNTX:
- H.C. Wainwright Sticks to Their Hold Rating for Onconova Therapeutics (ONTX)
- H.C. Wainwright Keeps Their Buy Rating on iTeos Therapeutics (ITOS)
- H.C. Wainwright Keeps Their Buy Rating on Dice Therapeutics (DICE)
- H.C. Wainwright Remains a Buy on Nkarta (NKTX)
- H.C. Wainwright Sticks to Their Buy Rating for Janux Therapeutics Inc (JANX)
